Abstract
In this chapter we introduce the hypothesis that the glutamine-cycling pathway participates in the pathogenesis of MS and might be prominently involved in the development of the systemic underlying metabolic derangement. In addition, we postulate the critical role that some enzymatic reactions occurring in the liver tissue, such as the transamination reactions, play in the pathogenesis of MS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.
Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006;83:1237–47.
Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311–26.
Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448–53.
Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. 2009;32:1678–83.
Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One. 2010;5:e15234.
Wurtz P, Makinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes. 2012;61:1372–80.
Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125:2222–31.
Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3:207–14.
Felig P, Marliss E, Cahill Jr GF. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811–6.
Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. J Clin Invest. 1998;101:1519–29.
Krebs M, Brehm A, Krssak M, et al. Direct and indirect effects of amino acids on hepatic glucose metabolism in humans. Diabetologia. 2003;46:917–25.
van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care. 2003;26:625–30.
Brand K, Von HJ, Langer K, Fekl W. Pathways of glutamine and glutamate metabolism in resting and proliferating rat thymocytes: comparison between free and peptide-bound glutamine. J Cell Physiol. 1987;132:559–64.
Lindblom P, Rafter I, Copley C, et al. Isoforms of alanine aminotransferases in human tissues and serum—differential tissue expression using novel antibodies. Arch Biochem Biophys. 2007;466:66–77.
Goessling W, Massaro JM, Vasan RS, D'Agostino Sr RB, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935–44.
Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the framingham heart study. Arterioscler Thromb Vasc Biol. 2013;33:139–46.
Qu HQ, Li Q, Grove ML, et al. Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population. Arch Med Res. 2012;43:482–8.
Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino Jr RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–7.
Kain K, Carter AM, Grant PJ, Scott EM. Alanine aminotransferase is associated with atherothrombotic risk factors in a British South Asian population. J Thromb Haemost. 2008;6:737–41.
Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–43.
Nguyen QM, Srinivasan SR, Xu JH, et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the bogalusa heart study. Diabetes Care. 2011;34:2603–7.
Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol. 2009;104:1715–22.
Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–92.
Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–95.
Sinner MF, Wang N, Fox CS, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013;111:219–24.
Burgueno AL, Gianotti TF, Mansilla NG, Pirola CJ, Sookoian S. Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1alpha in a rat model. Clin Sci (Lond). 2013;124:53–63.
Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol. 2012;18:3775–81.
Meton I, Mediavilla D, Caseras A, Canto E, Fernandez F, Baanante IV. Effect of diet composition and ration size on key enzyme activities of glycolysis-gluconeogenesis, the pentose phosphate pathway and amino acid metabolism in liver of gilthead sea bream (Sparus aurata). Br J Nutr. 1999;82:223–32.
Gray S, Wang B, Orihuela Y, et al. Regulation of gluconeogenesis by Kruppel-like factor 15. Cell Metab. 2007;5:305–12.
Thulin P, Rafter I, Stockling K, et al. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol. 2008;231:1–9.
Horio Y, Tanaka T, Taketoshi M, Uno T, Wada H. Rat cytosolic aspartate aminotransferase: regulation of its mRNA and contribution to gluconeogenesis. J Biochem. 1988;103:805–8.
Barbosa-Silva A, Fontaine JF, Donnard ER, Stussi F, Ortega JM, Andrade-Navarro MA. PESCADOR, a web-based tool to assist text-mining of biointeractions extracted from PubMed queries. BMC Bioinformatics. 2011;12:435.
Boutin P, Dina C, Vasseur F, et al. GAD2 on chromosome 10p12 is a candidate gene for human obesity. PLoS Biol. 2003;1:E68.
Meyre D, Boutin P, Tounian A, et al. Is glutamate decarboxylase 2 (GAD2) a genetic link between low birth weight and subsequent development of obesity in children? J Clin Endocrinol Metab. 2005;90:2384–90.
Choquette AC, Lemieux S, Tremblay A, et al. GAD2 gene sequence variations are associated with eating behaviors and weight gain in women from the Quebec family study. Physiol Behav. 2009;98:505–10.
Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214–20.
Ruderman NB, Xu XJ, Nelson L, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298:E751–60.
Oehler R, Roth E. Regulative capacity of glutamine. Curr Opin Clin Nutr Metab Care. 2003;6:277–82.
Sookoian S, Pirola CJ. Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep. 2011;13:149–57.
Stancakova A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012;61(7):1895–902.
Suhre K, Shin SY, Petersen AK, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54–60.
Krumsiek J, Suhre K, Evans AM, et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet. 2012;8:e1003005.
Adamski J, Suhre K. Metabolomics platforms for genome wide association studies-linking the genome to the metabolome. Curr Opin Biotechnol. 2013;24:39–47.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.
Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001–2006. Arch Pediatr Adolesc Med. 2009;163:371–7.
de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110:2494–7.
Barker DJ, Clark PM. Fetal undernutrition and disease in later life. Rev Reprod. 1997;2:105–12.
Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5–20.
Poston L. Gestational weight gain: influences on the long-term health of the child. Curr Opin Clin Nutr Metab Care. 2012;15:252–7.
Sookoian S, Fernandez GT, Burgueno A, Pirola CJ. Fetal metabolic programming and epigenetic modifications: a systems biology approach. Pediatr Res. 2013;73:531–42.
Hermanussen M, Tresguerres JA. Does the thrifty phenotype result from chronic glutamate intoxication? A hypothesis. J Perinat Med. 2003;31:489–95.
Battaglia FC. Glutamine and glutamate exchange between the fetal liver and the placenta. J Nutr. 2000;130:974S–7S.
Vaughn PR, Lobo C, Battaglia FC, Fennessey PV, Wilkening RB, Meschia G. Glutamine-glutamate exchange between placenta and fetal liver. Am J Physiol. 1995;268:E705–11.
Hermanussen M, Garcia AP, Sunder M, Voigt M, Salazar V, Tresguerres JA. Obesity, voracity, and short stature: the impact of glutamate on the regulation of appetite. Eur J Clin Nutr. 2006;60:25–31.
Funding Support
This study was partially supported by grants PICT 2008-1521 and 2010-0441 (Agencia Nacional de Promoción Científica y Tecnológica), and UBACYT CM04 (Universidad de Buenos Aires). SS and CJP belong to CONICET.
Potential competing interests
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sookoian, S., Pirola, C.J. (2015). Glutamine-Cycling Pathway in Metabolic Syndrome: Systems Biology-Based Characterization of the Glutamate-Related Metabolotype and Advances for Diagnosis and Treatment in Translational Medicine. In: Rajendram, R., Preedy, V., Patel, V. (eds) Glutamine in Clinical Nutrition. Nutrition and Health. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1932-1_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1932-1_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1931-4
Online ISBN: 978-1-4939-1932-1
eBook Packages: MedicineMedicine (R0)